Jin Ze-Jun, Wang Gen-Zhen
Department of Nephrology, Anhui Wannan Rehabilitation Hospital, Wuhu, Anhui, People's Republic of China.
Diabetes Metab Syndr Obes. 2023 Jul 22;16:2167-2175. doi: 10.2147/DMSO.S421579. eCollection 2023.
This study aimed to analyze the clinical efficacy of dapagliflozin in the treatment of diabetic kidney disease and its impact on proteinuria levels in patients.
Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from January 2020 to January 2022. According to the different treatment methods, the patients were divided into a control group (n=88) receiving enalapril maleate treatment and an observation group (n=88) receiving dapagliflozin treatment. The clinical treatment effects, blood glucose levels, renal function indicators, inflammation factor indicators, and adverse reactions were compared between the two groups.
The total effective rate of treatment (97.73%) in the observation group was significantly higher than that (79.55%) in the control group (P<0.05). After treatment, the FPG, 2hPG, and HbAlc levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the Scr, BUN, UmAlb, UAER, UACR, and 24-hour urine protein quantitative levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the hs-CRP, IL-1β, and TNF-α levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group significantly lower than the control group (P<0.05).
Compared with enalapril maleate alone, the combined application of dapagliflozin in the treatment of diabetic kidney disease has more significant clinical efficacy. It can further control patients' blood sugar, reduce their body's inflammatory response, alleviate or eliminate their proteinuria symptoms, promote the recovery of their renal function, and enhance the safety of their treatment to a certain extent, which helps to further improve the clinical treatment effect of patients.
本研究旨在分析达格列净治疗糖尿病肾病的临床疗效及其对患者蛋白尿水平的影响。
回顾性分析2020年1月至2022年1月在我院接受治疗的176例糖尿病肾病患者的病历。根据治疗方法的不同，将患者分为接受马来酸依那普利治疗的对照组（n = 88）和接受达格列净治疗的观察组（n = 88）。比较两组的临床治疗效果、血糖水平、肾功能指标、炎症因子指标及不良反应。
观察组的治疗总有效率（97.73%）显著高于对照组（79.55%）（P < 0.05）。治疗后，观察组的空腹血糖（FPG）、餐后2小时血糖（2hPG）和糖化血红蛋白（HbAlc）水平显著低于对照组（P < 0.05）。治疗后，观察组的血肌酐（Scr）、尿素氮（BUN）、尿微量白蛋白（UmAlb）、尿白蛋白排泄率（UAER）、尿白蛋白/肌酐比值（UACR）和24小时尿蛋白定量水平显著低于对照组（P < 0.05）。治疗后，观察组的超敏C反应蛋白（hs-CRP）、白细胞介素-1β（IL-1β）和肿瘤坏死因子-α（TNF-α）水平显著低于对照组（P < 0.05）。观察组的不良反应发生率显著低于对照组（P < 0.05）。
与单独使用马来酸依那普利相比，联合应用达格列净治疗糖尿病肾病具有更显著的临床疗效。它可以进一步控制患者血糖，减轻机体炎症反应，缓解或消除蛋白尿症状，促进肾功能恢复，并在一定程度上提高治疗安全性，有助于进一步改善患者的临床治疗效果。
